SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):4P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Edmunds, J. S.
Right arrow Articles by Coleman, R. E.
PubMed
Right arrow Articles by Edmunds, J. S.
Right arrow Articles by Coleman, R. E.

Neurosciences: Special Sessions

Brain Imaging Council Young Investigator Award Symposium

Novel 18F radioligand for PET imaging of Alzheimer's disease

J. Stewart Edmunds1, P. Murali Doraiswamy1, Jeffery R. Petrella1, Caroline Hellegers1, Thomas C. Hawk1, Timothy G. Turkington1, Pradeep Garg3, Michael J. Pontecorvo2 and R. Edward Coleman1

1 Duke University Hospital, Durham, North Carolina; 2 Avid Radiopharmaceuticals, Philadelphia, Pennsylvania; 3 Wake Forest University, Winston Salem, North Carolina


Formula

12

Objectives: Characterize uptake and distribution of a novel 18F labeled agent that binds with high affinity to amyloid plaque. Dynamic distribution patterns were compared between Alzheimer’s disease (AD) subjects and normal controls (NC).

Methods: With IRB approval, 13 research subjects [5 AD(3M,2F,77.8±5.3yr) and 8 NC(2M,6F,71.5±7.4yr)] received 5 mCi of a novel amyloid binding agent 18F-AV-144. Dynamic 3D PET brain imaging was performed for 90 minutes. PET emission data, coregistered with segmented MRI, allowed ROI generated lobar cortical grey matter (GM) activity comparisons between AD subjects and NC. No adverse reactions observed.

Results: In comparing both frontal cortical to cerebellar activity (F/CBL) and total cortical GM to cerebellar activity (GM/CBL), the AD group demonstrated significantly greater GM 18F-AV-144 retention at all time points compared to NC. Normalized whole brain activity was also significantly greater in the AD subjects.


Figure 1
Cortical activity ratio comparisons between AD (n=5) and NC (n=8) at 30, 60, and 90 minutes. (F=frontal, GM=grey matter, CBL=cerebellar)

Conclusions: PET imaging with 18F-AV-144, a novel amyloid binding agent, differentiates Alzheimer’s disease patients from normal controls with high confidence. Results warrant further development of this 18F labeled PET imaging agent to quantify amyloid plaque burden in AD patients.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Edmunds, J. S.
Right arrow Articles by Coleman, R. E.
PubMed
Right arrow Articles by Edmunds, J. S.
Right arrow Articles by Coleman, R. E.